Releasing the Brakes on Cancer Immunotherapy.
From the Department of Medicine, Division of Hematology-Oncology, and the Jonsson Comprehensive Cancer Center, University of California Los Angeles, Los Angeles.
Antoni
A
Ribas
D000818:Animals; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000037:antagonists & inhibitors* / Q000502:physiology; D006801:Humans; D007167:Immunotherapy; D008198:Lymph Nodes / Q000276:immunology; D008213:Lymphocyte Activation / Q000502:physiology; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D013601:T-Lymphocytes / Q000502:physiology*
D000911:Antibodies, Monoclonal; D060908:CTLA-4 Antigen; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor